Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293715072> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4293715072 endingPage "468" @default.
- W4293715072 startingPage "464" @default.
- W4293715072 abstract "Abstract
 Objective: 
 Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor imaging has been widely used in recent years. However, there are conflicting publications in the literature, although there are guidelines for discontinuing the use of SSA before imaging. This study aims to investigate the effect of SSAs on Somatostatin receptor imaging.
 Material and Method: We retrospectively analyzed 253 patients who underwent 68Ga-DOTATATE PET/CT imaging between 2018 and 2022. Among these patients, those with low grades (Grade 1 and Grade 2) using SSA were included in the study. SUVmax (maximum standard uptake volume) of normal target organs, primary tumors, and metastases with the highest SUVmax in each organ were compared before and after SSA treatment. 
 Results: 28 patients (16 females; 12 males, age [mean±SD], 54.82±14.27, range 18-78) with low-grade (Grade 1 and 2) NET and 68Ga-DOTATATE PET/CT imaging with SSA therapy were included in the study. Although SUVmax was decreased in the values measured after SSA application in the liver and spleen, it was not statistically significant (p>0.05). There was no significant difference between SUVmax values in primary tumors and metastatic lesions in the liver, bone, lung, or lymph nodes before and after SSA application (P> 0.05).
 Conclusion: In conclusion, these drugs do not need to be discontinued before 68Ga-DOTATATE PET/CT imaging for treatment follow-up in neuroendocrine tumor patients using somatostatin analogs. In addition, these drugs may help report interpretation by increasing the intensity of metastatic lesions in the liver and spleen." @default.
- W4293715072 created "2022-08-31" @default.
- W4293715072 creator A5005938192 @default.
- W4293715072 creator A5013234392 @default.
- W4293715072 creator A5066313508 @default.
- W4293715072 creator A5066535952 @default.
- W4293715072 creator A5066935547 @default.
- W4293715072 creator A5090135674 @default.
- W4293715072 date "2022-08-31" @default.
- W4293715072 modified "2023-09-26" @default.
- W4293715072 title "68Ga-DOTATATE PET/BT görüntülemede somatostatin analogları ile tedavi normal hedef organların ve malign lezyonların alımında farklılık gösterir mi?" @default.
- W4293715072 cites W1987719339 @default.
- W4293715072 cites W2028086728 @default.
- W4293715072 cites W2030326754 @default.
- W4293715072 cites W2061519720 @default.
- W4293715072 cites W2068937483 @default.
- W4293715072 cites W2086608867 @default.
- W4293715072 cites W2122196655 @default.
- W4293715072 cites W2156178856 @default.
- W4293715072 cites W2157129652 @default.
- W4293715072 cites W2232569012 @default.
- W4293715072 cites W2321745733 @default.
- W4293715072 cites W2402411674 @default.
- W4293715072 cites W2619499717 @default.
- W4293715072 cites W2737024591 @default.
- W4293715072 cites W2784632911 @default.
- W4293715072 cites W2789282818 @default.
- W4293715072 cites W2940207815 @default.
- W4293715072 cites W2963983295 @default.
- W4293715072 doi "https://doi.org/10.54005/geneltip.1157941" @default.
- W4293715072 hasPublicationYear "2022" @default.
- W4293715072 type Work @default.
- W4293715072 citedByCount "0" @default.
- W4293715072 crossrefType "journal-article" @default.
- W4293715072 hasAuthorship W4293715072A5005938192 @default.
- W4293715072 hasAuthorship W4293715072A5013234392 @default.
- W4293715072 hasAuthorship W4293715072A5066313508 @default.
- W4293715072 hasAuthorship W4293715072A5066535952 @default.
- W4293715072 hasAuthorship W4293715072A5066935547 @default.
- W4293715072 hasAuthorship W4293715072A5090135674 @default.
- W4293715072 hasBestOaLocation W42937150721 @default.
- W4293715072 hasConcept C126322002 @default.
- W4293715072 hasConcept C127077266 @default.
- W4293715072 hasConcept C2775842073 @default.
- W4293715072 hasConcept C2776297358 @default.
- W4293715072 hasConcept C2779066768 @default.
- W4293715072 hasConcept C2989005 @default.
- W4293715072 hasConcept C71924100 @default.
- W4293715072 hasConcept C80115893 @default.
- W4293715072 hasConceptScore W4293715072C126322002 @default.
- W4293715072 hasConceptScore W4293715072C127077266 @default.
- W4293715072 hasConceptScore W4293715072C2775842073 @default.
- W4293715072 hasConceptScore W4293715072C2776297358 @default.
- W4293715072 hasConceptScore W4293715072C2779066768 @default.
- W4293715072 hasConceptScore W4293715072C2989005 @default.
- W4293715072 hasConceptScore W4293715072C71924100 @default.
- W4293715072 hasConceptScore W4293715072C80115893 @default.
- W4293715072 hasIssue "4" @default.
- W4293715072 hasLocation W42937150721 @default.
- W4293715072 hasLocation W42937150722 @default.
- W4293715072 hasOpenAccess W4293715072 @default.
- W4293715072 hasPrimaryLocation W42937150721 @default.
- W4293715072 hasRelatedWork W158565870 @default.
- W4293715072 hasRelatedWork W171340045 @default.
- W4293715072 hasRelatedWork W2033480787 @default.
- W4293715072 hasRelatedWork W2105705536 @default.
- W4293715072 hasRelatedWork W2138922322 @default.
- W4293715072 hasRelatedWork W2149662789 @default.
- W4293715072 hasRelatedWork W2321353203 @default.
- W4293715072 hasRelatedWork W2939814203 @default.
- W4293715072 hasRelatedWork W3134814397 @default.
- W4293715072 hasRelatedWork W3165313794 @default.
- W4293715072 hasVolume "32" @default.
- W4293715072 isParatext "false" @default.
- W4293715072 isRetracted "false" @default.
- W4293715072 workType "article" @default.